Generic Makers Defend Legality of Reverse Patent Settlements, Urge SCOTUS to Rule Against FTC

The Supreme Court should let stand an 11th Circuit Court decision that upheld the legality of reverse patent settlements between brand- and generic-drug makers, urge Actavis and Par, which are both parties to the upcoming high court case. The FTC argues that reverse patent settlements are presumptively illegal unless proven otherwise, but this position “writes the patent out of the equation entirely,” Actavis argues in its brief.
Drug Industry Daily